Thera-SAbDab

TIDUTAMAB

> Structural Summary

Therapeutic	Tidutamab
Target 1	SSTR2
Heavy Chain 1	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMAWFRQAPGKGLEWVSFISNLGYSIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAPYDYDSFDPMDYWGQGTLVTVSS
Light Chain 1	DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRNRKNYLAWYQQKPDQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYYLWTFGGGTKVEIK
100% seqID Fv 1 Structure	None
99% seqID Fv 1 Structure	None
95-98% seqID Fv 1 Structure	None
Target 2	CD3E
Heavy Chain 2	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS
Light Chain 2	QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL
100% seqID Fv 2 Structure	None
99% seqID Fv 2 Structure	None
95-98% seqID Fv 2 Structure	None

There are currently no PDB structures close in sequence to either Fv of this therapeutic. Click the links to build models with ABodyBuilder: [Fv 1] [Fv 2]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder: [Fv 1] [Fv 2]
Test for possible therapeutic developability issues with TAP: [Fv 1] [Fv 2]
Assign canonical forms by sequence with SCALOP: [Fv 1] [Fv 2]
Number the sequences in any numbering scheme with ANARCI: [Fv 1 H] [Fv 1 L] [Fv 2 H] [Fv 2 L]

Format	Bispecific Mixed mAb and scFv
Isotype	G1
Highest Clinical Trial (Jan '20)	Phase-I
Estimated Status (Jan '20)	Active
Recorded Developmental Technology	na
INN Year Proposed	2018
INN Year Recommended	None
Companies Involved	ICON, Xencor
Conditions Approved	na
Conditions Active	Gastrointestinal stromal tumours, Neuroendocrine tumours
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]